Pill Identification: ZP 10
A small orange round tablet imprinted with "ZP 10" on one side and blank on the reverse is most commonly identified as Olanzapine 10 mg, an atypical antipsychotic medication.
Medication Overview
Olanzapine is a thienobenzodiazepine derivative atypical antipsychotic used primarily for schizophrenia and bipolar disorder management 1, 2.
- The standard starting dose is 10 mg as a single daily dose 2
- Peak plasma levels are reached in 5-8 hours with a half-life of approximately 35 hours 2
- The recommended maximum dose is 20 mg daily, though higher doses have been employed 2
Clinical Indications
Olanzapine is approved for:
- Oral treatment of schizophrenia 3
- Acute manic episodes in patients with bipolar disorder 3
- Maintenance therapy to prevent recurrence in responders 3
Mechanism and Efficacy
- Olanzapine has greater affinity for serotonin 5-HT2A receptors than dopamine D2 receptors, distinguishing it from conventional antipsychotics 1
- It demonstrates superior efficacy compared to haloperidol in treating negative and depressive symptoms of schizophrenia 1
- The drug shows comparable or superior efficacy to risperidone with a favorable side-effect profile 2
Common Adverse Effects
The most frequently reported side effects include:
- Weight gain (occurs in approximately 40% of patients, especially with high starting doses) 2
- Somnolence 1, 2
- Dizziness 1
- Anticholinergic effects including dry mouth and constipation 1
- Transient asymptomatic liver enzyme elevations 1
Critical Safety Considerations
- Olanzapine is not associated with agranulocytosis risk (unlike clozapine) or clinically significant hyperprolactinemia (unlike risperidone) 1
- No QTc interval prolongation concerns, eliminating the need for baseline ECG monitoring 2
- Significantly fewer extrapyramidal symptoms compared to haloperidol and risperidone 1
Generic Formulations
- Generic olanzapine 10 mg tablets have demonstrated bioequivalence to brand-name formulations, with 90% confidence intervals for pharmacokinetic parameters falling within the 80-125% regulatory criteria 3
- Studies show similar relapse rates and no untoward side effects when switching from brand to generic olanzapine 4